Teva Pharmaceutical Industries Limited
HealthcareNYSE:TEVA · New York Stock Exchange
+$0.07 today
Vol 4.51M · Avg 6.41M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
17.8%
avg -17.9%
ROIC
7.4%
avg -2.6%
ROA
3.5%
avg -3.6%
Analysis
ROE is currently the strongest return metric at 17.8% versus its period average of -17.9%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Richard Francis | President, Chief Executive Officer & Director | $7.17M | — | 58 | $39,130.00 | <0.01% |
Eliyahu Sharon Kalif | Executive Vice President & Chief Financial Officer | $3.16M | — | 52 | $172,184.00 | 0.01% |
Eric A. Hughes | Executive Vice President of Global R&D and Chief Medical Officer | $2.55M | — | 56 | $117,244.00 | 0.01% |
Christine Fox | Executive VP of US Commercial & Head of Innovative Franchise | $2.50M | — | 57 | $63,647.00 | <0.01% |
Evan Lippman | Executive Vice President of Business Development | $2.32M | — | 56 | $44,191.00 | <0.01% |
Matthew Shields | Executive Vice President of Global Operations | $2.25M | — | 51 | $26,184.00 | <0.01% |
Placid Jover | Executive Vice President & CHRO | — | — | 44 | $42,453.00 | <0.01% |
Amir Weiss | Senior Vice President & Chief Accounting Officer | — | — | 49 | $2.12M | 0.18% |
Christopher J. Stevo | Senior Vice President of Investor Relations & Competitive Intelligence | — | — | — | — | — |
Kathleen Veit | Senior Vice President, Global Compliance & Ethics Officer | — | — | — | — | — |
Brian Savage | Interim Chief Legal Officer | — | — | — | $12,041.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$20,988.06
Sells
46
$92.11M
Net Sentiment
$92.09M
Net selling
Most Active
Francis Richard D
7 transactions
1–10 of 47
Analysis
Insiders reported 1 buys worth $20,988.06 and 46 sells worth $92.11M over the last 12 months. That adds up to net selling of $92.09M. Francis Richard D was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | -6.8% | +5.9% (15yr)1 analysts |
| Revenue | N/A | N/A | -1.1% | -0.1% (15yr)7 analysts |
| Net Income | N/A | N/A | -6.8% | +8.0% (15yr)7 analysts |
| EBIT | N/A | N/A | +15.0% | -5.1% (15yr)7 analysts |
Analysis
Recent growth has been strongest in EBIT at +15.0% over three years. Forward estimates point to Net Income at +8.0% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Natera, Inc.
NASDAQ:NTRA
$30.37B
Biogen Inc.
NASDAQ:BIIB
$29.53B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
Waters Corporation
NYSE:WAT
$23.17B
BioNTech SE
NASDAQ:BNTX
$22.90B
Labcorp Holdings Inc.
NYSE:LH
$21.83B
STERIS plc
NYSE:STE
$20.26B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
Insulet Corporation
NASDAQ:PODD
$10.37B
Who manages TEVA?
Teva Pharmaceutical Industries Limited (TEVA) lists 11 active executives. The top listed executive is Eric A. Hughes, Executive Vice President of Global R&D and Chief Medical Officer.
Are TEVA insiders buying or selling?
Recent insider activity shows net selling of $93.04M.
Explore More
Continue the stock analysis
Jump to another research area for this company.